Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430507 | 1.00 | FABP5 (0.48) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL3491073 | 0.87 | FABP5 (0.39) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL4478311 | 0.85 | FABP5 (0.36) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL30876356 | 0.84 | FABP5 (0.46) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL622854 | 0.84 | FABP5 (0.46) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL15789977 | 0.84 | FABP5 (0.44) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL17941734 | 0.82 | KMT2A (0.47) | FABP5FABP7KMT2AEPHX2MDM4 | |
| SCHEMBL6206197 | 0.81 | TSHR (0.48) | TSHR | |
| SCHEMBL5663756 | 0.81 | FABP5 (0.43) | FABP5FABP7KMT2ATSHREPHX2 | |
| SCHEMBL3194549 | 0.80 | POLB (0.37) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005503256-A | — | — | 2005-02-03 | — | — | JP | claimed |
| US-20040242915-A1 | Modified alumina catalyst | BIOCON LIMITED (IN) | 2004-12-02 | — | — | US | claimed |
| EP-1427526-A1 | MODIFIED ALUMINA CATALYST | Biocon Limited (IN) | 2004-06-16 | — | — | EP | claimed |
| WO-2003024591-A1 | MODIFIED ALUMINA CATALYST | BIOCON LIMITED (IN) | 2003-03-27 | — | — | WO | claimed |
| US-6127129-A | DEPOSITING OMEGA MODIFIED ALKANETHIOL MONOLAYER, BLOCKING WITH HYDROPHOBIC PROTECTING GROUPS, PATTERNING, DEPOSITING AGAIN IN EXPOSED AREAS, ATTACHING MOLECULES/CELLS TO THOSE SPOTS, DEBLOCKING, MAKING RESISTANT TO NON-SPECIFIC PROTEIN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-10-03 | — | — | US | claimed |
| EP-0618219-A1 | Procedure for obtaining carbocalcitonin | LIPOTEC, S.A. (ES) | 1994-10-05 | — | — | EP | claimed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20250237656-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| CN-112105625-B | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 赛诺菲 | 2024-12-31 | — | — | CN | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-1991019735-A1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT PAUL A (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0433112-A1 | Modified gangliosides and the functional derivatives thereof | FIDIA S.p.A. (IT) | 1991-06-19 | — | — | EP | disclosed |
| EP-0431784-A2 | Methods for treating retroviral infection | ELI LILLY AND COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
| EP-0410881-A2 | Semisynthetic ganglioside analogues | FIDIA S.p.A. (IT) | 1991-01-30 | — | — | EP | disclosed |
| EP-0410883-A2 | Di-lysogangliosides derivatives | FIDIA S.p.A. (IT) | 1991-01-30 | — | — | EP | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0373039-A2 | New lysoganglioside derivatives | FIDIA S.p.A. (IT) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2427/4885FABP7 2559/4885KMT2A 2735/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | FABP5 4131/4885FABP7 3185/4885KMT2A 1794/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FABP5 2253/4885FABP7 2379/4885KMT2A 2325/4885 |
| US-20040242915-A1 | Modified alumina catalyst | ADH1A, APEX1, AAAS | FABP5 4126/4885FABP7 3632/4885KMT2A 268/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | FABP5 3246/4885FABP7 3421/4885KMT2A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.